On September 8, 2022 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, reported that it will be participating in the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022 (Press release, Actinium Pharmaceuticals, SEP 8, 2022, https://ir.actiniumpharma.com/news/detail/422/actinium-pharmaceuticals-to-participate-in-the-h-c-wainwright-24th-annual-global-investment-conference [SID1234619230]). The conference will be hybrid and occur virtually and in person at the Lotte New York Palace Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of Actinium’s management team will conduct one-on-one meetings. Please contact your representative at H.C. Wainwright to schedule a one-on-one meeting with the Actinium management team. For information about the H.C. Wainwright Global Investment Conference, please refer to the event’s website. Actinium’s investor presentation will be available on the conference website as well the investor relations page of the Company’s website at www.actiniumpharma.com/presentations-webinars.